Header Logo

Connection

JIUN-KAE JACK LEE to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Antineoplastic Agents.
JIUN-KAE JACK LEE
Connection Strength
0.788
Antineoplastic Agents
  1. Demystify statistical significance--time to move on from the p value to bayesian analysis. J Natl Cancer Inst. 2011 Jan 05; 103(1):2-3.
    View in: PubMed
    Score: 0.075
  2. Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev Res (Phila). 2010 Jun; 3(6):738-44.
    View in: PubMed
    Score: 0.072
  3. Re: Cancer chemoprevention: progress and promise. J Natl Cancer Inst. 1999 Mar 17; 91(6):563-5.
    View in: PubMed
    Score: 0.033
  4. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.026
  5. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25.
    View in: PubMed
    Score: 0.026
  6. drexplorer: A tool to explore dose-response relationships and drug-drug interactions. Bioinformatics. 2015 May 15; 31(10):1692-4.
    View in: PubMed
    Score: 0.025
  7. Clinical targeting of VEGF and EGFR effective in non-small cell lung cancer. Cancer Biol Ther. 2004 Jul; 3(7):588-9.
    View in: PubMed
    Score: 0.024
  8. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014 Jul 15; 20(14):3849-61.
    View in: PubMed
    Score: 0.024
  9. Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin Cancer Res. 2013 Aug 15; 19(16):4305-8.
    View in: PubMed
    Score: 0.022
  10. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
    View in: PubMed
    Score: 0.022
  11. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst. 2013 Jun 05; 105(11):833.
    View in: PubMed
    Score: 0.022
  12. Reply to A. Levy et al. J Clin Oncol. 2013 Jan 20; 31(3):396.
    View in: PubMed
    Score: 0.022
  13. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84.
    View in: PubMed
    Score: 0.021
  14. Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer. Int J Oncol. 2012 Nov; 41(5):1798-808.
    View in: PubMed
    Score: 0.021
  15. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20; 30(27):3345-52.
    View in: PubMed
    Score: 0.021
  16. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012 Jul 20; 30(21):2684-90.
    View in: PubMed
    Score: 0.021
  17. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012 Jul 01; 18(13):3705-13.
    View in: PubMed
    Score: 0.021
  18. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010 Feb 15; 16(4):1289-97.
    View in: PubMed
    Score: 0.018
  19. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila). 2010 Feb; 3(2):148-59.
    View in: PubMed
    Score: 0.018
  20. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010 Jan 10; 28(2):193-201.
    View in: PubMed
    Score: 0.018
  21. Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells. Technol Cancer Res Treat. 2009 Apr; 8(2):163-76.
    View in: PubMed
    Score: 0.017
  22. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21.
    View in: PubMed
    Score: 0.016
  23. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6.
    View in: PubMed
    Score: 0.016
  24. A predictive probability design for phase II cancer clinical trials. Clin Trials. 2008; 5(2):93-106.
    View in: PubMed
    Score: 0.015
  25. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst. 2007 Nov 07; 99(21):1603-12.
    View in: PubMed
    Score: 0.015
  26. Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat. 2007; 17(3):461-80.
    View in: PubMed
    Score: 0.014
  27. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31.
    View in: PubMed
    Score: 0.014
  28. 9-cis-retinoic acid treatment increases serum concentrations of alpha-tocopherol in former smokers. Clin Cancer Res. 2005 Mar 15; 11(6):2305-11.
    View in: PubMed
    Score: 0.013
  29. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst. 2003 Feb 05; 95(3):206-14.
    View in: PubMed
    Score: 0.011
  30. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J Clin Oncol. 2001 Mar 01; 19(5):1493-500.
    View in: PubMed
    Score: 0.010
  31. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000 Feb; 18(3):609-22.
    View in: PubMed
    Score: 0.009
  32. Accrual strategies for phase I trials with delayed patient outcome. Stat Med. 1999 May 30; 18(10):1155-69.
    View in: PubMed
    Score: 0.008
  33. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res. 1998 Feb; 4(2):303-10.
    View in: PubMed
    Score: 0.008
  34. Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Oncol. 1997 Jan; 8(1):85-9.
    View in: PubMed
    Score: 0.007
  35. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996 Feb; 14(2):503-13.
    View in: PubMed
    Score: 0.007
  36. Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol. 1996 Jan; 14(1):287-95.
    View in: PubMed
    Score: 0.007
  37. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014 May 15; 5(9):2349-54.
    View in: PubMed
    Score: 0.006
  38. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014 Jun; 25(6):1184-92.
    View in: PubMed
    Score: 0.006
  39. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
    View in: PubMed
    Score: 0.006
  40. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75.
    View in: PubMed
    Score: 0.005
  41. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
    View in: PubMed
    Score: 0.005
  42. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene. 2011 Jul 14; 30(28):3163-73.
    View in: PubMed
    Score: 0.005
  43. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009 May 20; 101(10):708-20.
    View in: PubMed
    Score: 0.004
  44. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50.
    View in: PubMed
    Score: 0.003
  45. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology. 2001 Apr; 57(4 Suppl 1):4-27.
    View in: PubMed
    Score: 0.002
  46. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998 Oct 21; 90(20):1545-51.
    View in: PubMed
    Score: 0.002
  47. Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancer. Cancer Epidemiol Biomarkers Prev. 1997 Sep; 6(9):687-92.
    View in: PubMed
    Score: 0.002
  48. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res. 1996 Oct; 2(10):1787-93.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.